[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100633258":3},{"organization":4,"outcomesModule":7,"designInfo":40,"detailedDescription":11,"studyPopulation":11,"armGroups":46,"interventions":52,"overallOfficials":11,"centralContacts":57,"locations":63,"responsibleParty":127,"collaborators":11,"id":129,"slug":130,"hasResults":131,"nctId":132,"briefTitle":133,"officialTitle":134,"acronym":11,"eligibilityCriteria":135,"healthyVolunteers":131,"sex":136,"minAge":137,"maxAge":11,"enrollmentInfo":138,"targetDuration":11,"studyType":141,"phases":142,"briefSummary":144,"conditions":145,"keywords":11,"overallStatus":66,"whyStopped":11,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":148,"startDateStruct":151,"completionDateStruct":153,"leadSponsor":155,"locationsCount":156},{"fullName":5,"class":6},"Samsung Bioepis Co., Ltd.","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":20,"otherOutcomes":11},[9,13,16],{"measure":10,"description":11,"timeFrame":12},"Incidence of adverse events and serious adverse events",null,"Until trial completion (estimated 3 years)",{"measure":14,"description":11,"timeFrame":15},"Incidence of dose limiting toxicity","For the first cycle of treatment, through pre-dose Cycle 2 Day 1",{"measure":17,"description":18,"timeFrame":19},"Confirmed objective response rate","Efficacy endpoint per Blinded Independent Central Review (BICR), according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1","32 weeks",[21,24,26,28,30,32,34,36,38],{"measure":22,"description":23,"timeFrame":19},"Tumor response","Efficacy endpoint per BICR, according to RECIST v1.1",{"measure":25,"description":23,"timeFrame":19},"Disease control rate",{"measure":27,"description":11,"timeFrame":12},"Area under the plasma\u002Fserum concentration vs time curve of total E303",{"measure":29,"description":11,"timeFrame":12},"Maximum plasma\u002Fserum concentration of total E303",{"measure":31,"description":11,"timeFrame":12},"Time to reach maximum plasma\u002Fserum concentration of total E303",{"measure":33,"description":11,"timeFrame":12},"Plasma\u002Fserum concentration before the next dose of total E303",{"measure":35,"description":11,"timeFrame":12},"Terminal half life of total E303",{"measure":37,"description":11,"timeFrame":12},"Incidence and titer of anti-drug antibodies",{"measure":39,"description":11,"timeFrame":12},"Incidence of neutralizing antibodies",{"allocation":41,"interventionModel":42,"interventionModelDescription":11,"primaryPurpose":43,"observationalModel":11,"timePerspective":11,"maskingInfo":44},"NA","SEQUENTIAL","TREATMENT",{"masking":45,"maskingDescription":11,"whoMasked":11},"NONE",[47],{"label":48,"type":49,"description":11,"interventionNames":50},"E303","EXPERIMENTAL",[51],"Drug: E303",[53],{"type":54,"name":48,"description":55,"armGroupLabels":56,"otherNames":11},"DRUG","All participants will receive an intravenous (IV) infusion of E303",[48],[58],{"name":59,"role":60,"phone":61,"phoneExt":11,"email":62},"Samsung Bioepis","CONTACT","+82-32-728-0114","bioepisinfo@samsung.com",[64,78,87,96,103,111,120],{"facility":65,"status":66,"city":67,"state":68,"zip":69,"country":70,"countryCode":71,"cosmosGeoPoint":72,"geoPoint":77,"contacts":11},"Research Site","RECRUITING","Scottsdale","Arizona","85258","United States","US",{"type":73,"coordinates":74},"Point",[75,76],-111.89903,33.50921,{"lat":76,"lon":75},{"facility":65,"status":66,"city":79,"state":80,"zip":81,"country":70,"countryCode":71,"cosmosGeoPoint":82,"geoPoint":86,"contacts":11},"Fairfax","Virginia","22031",{"type":73,"coordinates":83},[84,85],-77.30637,38.84622,{"lat":85,"lon":84},{"facility":65,"status":66,"city":88,"state":11,"zip":11,"country":89,"countryCode":90,"cosmosGeoPoint":91,"geoPoint":95,"contacts":11},"Adelaide","Australia","AU",{"type":73,"coordinates":92},[93,94],138.59863,-34.92866,{"lat":94,"lon":93},{"facility":65,"status":66,"city":97,"state":11,"zip":11,"country":89,"countryCode":90,"cosmosGeoPoint":98,"geoPoint":102,"contacts":11},"Melbourne",{"type":73,"coordinates":99},[100,101],144.96332,-37.814,{"lat":101,"lon":100},{"facility":65,"status":66,"city":104,"state":11,"zip":11,"country":105,"countryCode":11,"cosmosGeoPoint":106,"geoPoint":110,"contacts":11},"Seoul","South Korea",{"type":73,"coordinates":107},[108,109],126.9784,37.566,{"lat":109,"lon":108},{"facility":65,"status":66,"city":112,"state":11,"zip":11,"country":113,"countryCode":114,"cosmosGeoPoint":115,"geoPoint":119,"contacts":11},"Barcelona","Spain","ES",{"type":73,"coordinates":116},[117,118],2.15899,41.38879,{"lat":118,"lon":117},{"facility":65,"status":66,"city":121,"state":11,"zip":11,"country":113,"countryCode":114,"cosmosGeoPoint":122,"geoPoint":126,"contacts":11},"Madrid",{"type":73,"coordinates":123},[124,125],-3.70256,40.4165,{"lat":125,"lon":124},{"type":128,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100633258","phase-1-a-trial-to-investigate-the-safety-of-e303-in-participants-with-advanced-refractory-solid-tumors-100633258",false,"NCT07524348","A Trial to Investigate the Safety of E303 in Participants With Advanced Refractory Solid Tumors","A Phase I, Open-Label, Multi-Center, First-in-Human Trial to Investigate E303, in Participants With Advanced Refractory Solid Tumors","Inclusion Criteria:\n\n* Histologically-confirmed, locally advanced (unresectable) or metastatic solid tumors with recurrence or progression during or after standard therapy, intolerance to standard therapy, refused to receive standard therapy, or for whom no standard therapy is available.\n\nExclusion Criteria:\n\n* Have spinal cord compression or clinically active central nervous system metastases\n* Have leptomeningeal disease\n* Have thromboembolic or clinically significant bleeding events\n* Have significant cardiovascular disease\n* Have an active autoimmune disease","ALL","18 Years",{"count":139,"type":140},149,"ESTIMATED","INTERVENTIONAL",[143],"PHASE1","This is a Phase I trial to evaluate the safety, tolerability and efficacy of nectin-4 targeting antibody-drug conjugate (SBE303) in participants with advanced solid tumors",[146],"Advanced Solid Tumors","2026-09-30",{"date":149,"type":150},"2026-10-01","ACTUAL",{"date":152,"type":150},"2026-03-23",{"date":154,"type":140},"2030-07",{"name":5,"class":6},7]